低剂量治疗轻度认知障碍:试点随机临床试验
Ariel G Gildengers1, Tamer S Ibrahim2, Stewart J Anderson3
1Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
JAMA neurology
|March 2, 2026
概括
这项试点研究发现低剂量碳酸对轻度认知障碍 (MCI) 是可行的和安全的. 虽然没有达到显著的意义,但显示出缓慢MCI患者认知衰退的趋势.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 缺乏与阿尔茨海默氏症的病原发生有关.
- 之前没有任何随机临床试验研究过对轻度认知障碍 (MCI) 的认知,神经成像和血生物标志物的影响.
研究的目的:
- 评估碳酸在被诊断为MCI的老年人中延缓认知衰退的可行性,安全性和初步疗效.
- 为未来研究MCI的低剂量干预建立效果大小估计.
主要方法:
- 一个单位,随机,双盲,安慰剂控制的试点可行性试验,涉及83名患有MCI的成年人 (60岁以上).
- 参与者每天接受低剂量的碳酸或安慰剂两年,使用线性混合效应模型进行后续分析.
- 六个共同初级结果包括认知表现 (CVLT-II,BVMT-R,临床前阿尔茨海默氏症认知复合物),海马体积,皮质灰质体积和来自大脑的神经营养因子.
主要成果:
- 六个共同初级结果中没有一个达到统计学意义.
- 一个趋势表明,可能会减缓认知衰退,与安慰剂相比,CVLT-II延迟回忆的差异为0.69点/年 (P=.05).
- 不良事件在各组之间是相似的;没有严重事件是绝对与治疗相关的.
结论:
- 试点试验表明,低剂量碳酸对患有MCI的人来说是可行的,安全的和可以容忍的.
- 虽然这项研究没有统计学意义,但它提供了有价值的效果大小估计,并表明在减缓认知衰退方面具有潜在的益处,因此需要进一步调查.
更多相关视频
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
7.9K
08:53Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
1.9K
相关概念视频
01:24Mania and Antimanic Drugs: Overview
708
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
708
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
751
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
751
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K